会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明申请
    • Communication device management program
    • 通讯设备管理程序
    • US20050141444A1
    • 2005-06-30
    • US11014680
    • 2004-12-16
    • Koichi Hirai
    • Koichi Hirai
    • G06F13/28H04Q7/00
    • G06F13/28H04L49/90Y10S707/99931Y10S707/99932Y10S707/99933Y10S707/99934Y10S707/99935Y10S707/99936Y10S707/99937Y10S707/99938Y10S707/99939Y10S707/99954Y10S707/99955Y10S707/99956
    • A communication device management program that enables efficient use of memory space in receiving data using remote direct memory access (RDMA) techniques. The receiving node transmits a virtual ID corresponding to a receiving process to a remote sending node. A sending process in the sending node specifies this virtual ID when starting data transmission. If the receiving node has not reserved a memory area corresponding to that virtual ID, the sending node transmits a reservation request to the receiving node, which causes a data receiving memory area to be reserved for use by a communication device in the receiving node. In the sending node, the sending communication device begins sending transmission data in RDMA mode, from a memory area managed by the sending process to the reserved data receiving memory area. The receiving communication device directs incoming transmission data to a memory area managed by the receiving process.
    • 一种通信设备管理程序,其能够使用远程直接存储器访问(RDMA)技术有效地使用存储器空间来接收数据。 接收节点将与接收处理相对应的虚拟ID发送到远程发送节点。 发送节点的发送过程在开始数据传输时指定该虚拟ID。 如果接收节点没有预留与该虚拟ID相对应的存储区域,则发送节点向接收节点发送预约请求,这导致数据接收存储区域被保留以供在接收节点中的通信设备使用。 在发送节点中,发送通信装置从RDMA模式开始,从由发送处理的存储区域发送到保留数据接收存储区域的发送数据。 接收通信设备将传入的传输数据引导到由接收处理管理的存储区域。
    • 6. 发明授权
    • Methyl methacrylate syrup composition
    • 甲基丙烯酸甲酯糖浆组合物
    • US4617367A
    • 1986-10-14
    • US675568
    • 1984-11-28
    • Katsushi WatanabeTakafumi KageyamaTaisaku KanoKoichi HiraiYoshinobu Ichihara
    • Katsushi WatanabeTakafumi KageyamaTaisaku KanoKoichi HiraiYoshinobu Ichihara
    • C08F265/06C08F220/14
    • C08F265/06
    • A methyl methacrylate syrup composition comprises an intimate mixture of 1-99 parts by weight of a first polymer-in-monomer syrup (A) and 99-1 parts by weight of a second polymer-in-monomer syrup which can be either (B.sub.1) or (B.sub.2), wherein the syrups (A), (B.sub.1) and (B.sub.2) are as follows:(A) a polymer-in-monomer syrup obtained by copolymerizing a mixture of methyl methacrylate monomer, one or more monomers having reactivity with glycidyl groups and containing at least one ethylenically-unsaturated bond, and one or more of (meth)acrylates, styrene and styrene derivatives;(B.sub.1) a polymer-in-monomer syrup obtained by copolymerizing a mixture of one or more monomers containing at least one glycidyl group and at least one ethylenically-unsaturated bond, and one or more monomers selected from the group consisting of methyl methacrylate, (meth)acrylates, styrene and styrene derivatives;(B.sub.2) a polymer-in-monomer syrup containing a copolymer obtained by copolymerizing one or more monomers containing at least one glycidyl group and one or more other copolymerizable monomers, having a number average molecular weight of 1,500-50,000 and containing a glycidyl group, in one or more monomers selected from the group consisting of methyl methacrylate and (meth)acrylates, styrene and styrene derivatives.
    • 甲基丙烯酸甲酯糖浆组合物包含1-99重量份的第一单体聚合物糖浆(A)和99-1重量份的第二聚合物 - 单体糖浆的紧密混合物,其可以是(B1 )或(B2),其中糖浆(A),(B1)和(B2)如下:(A)通过使甲基丙烯酸甲酯单体,一种或多种具有反应性的单体的混合物的共聚合得到的聚合物单体混合物 含有至少一个烯属不饱和键的缩水甘油基和一种或多种(甲基)丙烯酸酯,苯乙烯和苯乙烯衍生物; (B1)通过将含有至少一个缩水甘油基和至少一个烯键式不饱和键的一种或多种单体的混合物和一种或多种选自甲基丙烯酸甲酯的单体(( 甲基)丙烯酸酯,苯乙烯和苯乙烯衍生物; (B2)含有共聚物的聚合物 - 单体浆液,所述共聚物通过共聚含有至少一个缩水甘油基的一种或多种单体和一种或多种其它可共聚单体,其数均分子量为1,500-50,000并含有缩水甘油基, 在一种或多种选自甲基丙烯酸甲酯和(甲基)丙烯酸酯,苯乙烯和苯乙烯衍生物的单体中。
    • 8. 发明授权
    • Amino-acid derivatives, their preparation and their use as
pharmaceuticals
    • 氨基酸衍生物,其制备及其作为药物的用途
    • US4545942A
    • 1985-10-08
    • US597817
    • 1984-04-09
    • Mitsuo NaganoKoichi HiraiKouichi KitamuraKenkichi ShinkaiHiroshi Yasuda
    • Mitsuo NaganoKoichi HiraiKouichi KitamuraKenkichi ShinkaiHiroshi Yasuda
    • A61K31/275A61K20060101A61K31/165A61K31/19A61K31/195A61K31/215A61P35/00A61P37/04C07C20060101C07C67/00C07C253/00C07C255/24C07C255/26C07C255/29C07C255/32C07C255/44C07C255/56C07C255/66C07D317/68C07C121/78
    • C07C255/00
    • New compounds useful as immunoregulatory and antineoplastic agents are amino-acid derivatives of formula: ##STR1## wherein: n is an integer from 1 to 5;R.sup.1 is a hydrogen atom, an alkyl group, a haloalkyl group, a halogen atom, a mercapto group, an alkylmercapto group, a hydroxy group, an alkoxy group, an acyloxy group, a carboxyl group, an alkoxycarbonyl group, an amino group, an alkyl-substituted amino group, an aryl-substituted amino group, an acylamino group, a haloalkoxycarbonylamino group, an alkanesulphonyl group, a nitro group or a cyano group (and, when n is an integer from 2 to 5, the radicals R.sup.1 may be the same or different);R.sup.2 and R.sup.3 may be the same or different and each is a hydrogen atom or an alkyl group;R.sup.4 is a hydrogen atom, an alkyl group, a cyano group, a cyanoalkyl group, a hydroxyalkyl group, an alkoxycarbonyl group, a carboxyl group, an aryl group, an aralkyl group, a mercaptoalkyl group, an alkylthioalkyl group, or a thioalkyl group (the free bond of the sulphur in said thioalkyl group being joined to the sulphur of another moiety of the same formula); andA is a hydroxy group, an alkoxy group, an amino group, an alkyl-substituted amino group (optionally halogen- or carbamoyl- substituted in the alkyl moiety), a hydrazino group, an alkyl- or aryl- substituted hydrazino group, a hydroxylamino group, an alkoxyamino group or an aralkyloxyamino group;and the pharmaceutically acceptable salts thereof.
    • 可用作免疫调节和抗肿瘤剂的新化合物是下式的氨基酸衍生物:其中:n是1至5的整数; R1是氢原子,烷基,卤代烷基,卤素原子,巯基,烷基巯基,羟基,烷氧基,酰氧基,羧基,烷氧基羰基,氨基, 烷基取代的氨基,芳基取代的氨基,酰氨基,卤代烷氧基羰基氨基,链烷磺酰基,硝基或氰基(当n为2至5的整数时,基团R 1可以 相同或不同); R2和R3可以相同或不同,各自为氢原子或烷基; R4是氢原子,烷基,氰基,氰基烷基,羟基烷基,烷氧基羰基,羧基,芳基,芳烷基,巯基烷基,烷硫基烷基或硫代烷基 (所述硫代烷基中的硫的游离键与相同式的另一部分的硫连接); 并且A是羟基,烷氧基,氨基,烷基取代的氨基(在烷基部分中任选被卤素取代或氨基甲酰基取代),肼基,烷基或芳基取代的肼基, 羟基氨基,烷氧基氨基或芳烷氧基氨基; 及其药学上可接受的盐。